Role of CREM in systemic lupus erythematosus

Cellular Immunology

Volumn 276, Issue 1-2, 2012, Pages 10-15

  Xu, Wang Dong ^a   Zhang, Yu Jing ^a   Wang, Wei ^a   Li, Rui ^a   Pan, Hai Feng ^a   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Autoimmune; CAMP response element modulator; Systemic lupus erythematosus

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; CD28 ANTIGEN; CD3 ANTIGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT MODULATOR; INTERLEUKIN 10; INTERLEUKIN 2; PROTEIN C FOS; PROTEIN KINASE SYK; PROTEIN P300;

CELLULAR DISTRIBUTION; CYTOKINE PRODUCTION; HUMAN; IMMUNE RESPONSE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TH17 CELL; TRANSCRIPTION REGULATION;

ANIMALS; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT MODULATOR; HUMANS; INTERLEUKINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROMOTER REGIONS, GENETIC; T-LYMPHOCYTES;

EID: 84863858849     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.04.008     Document Type: Review

References (67)

1. Liossis S.N., Sfikakis P.P., Tsokos G.C. Immune cell signaling aberrations in human lupus. Immunol. Res. 1998, 18:27-39.
2. Gerli R., Nocentini G., Alunno A., et al. Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun. Rev. 2009, 8:426-430.
3. Askenasy N., Kaminitz A., Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun. Rev. 2008, 7:370-375.
4. Okamoto A., Fujio K., Okamura T., et al. Regulatory T-cell-associated cytokines in systemic lupus erythematosys. J. Biomed. Biotechnol. 2011, 2011:463412.
5. Sharabi A., Mozes E. Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseases. Immunotherapy 2009, 1:385-401.
6. Crispin J.C., Martínez A., Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J. Autoimmun. 2003, 21:273-276.
7. Valencia X., Yarboro C., Illei G., et al. Deficient CD4+CD25 high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 2007, 178:2579-2588.
8. Hahn B.H., Anderson M., Le E., et al. Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008, 58:2488-2497.
9. Miyara M., Amoura Z., Parizot C., et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J. Immunol. 2005, 175:8392-8400.
10. Zhao X.F., Pan H.F., Yuan H., et al. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol. Biol. Rep. 2010, 37:81-86.
11. Li T.T., Zhang T., Chen G.M., et al. Low level of serum interleukin 27 in patients with systemic lupus erythematosus. J. Investig. Med. 2010, 58:737-739.
12. Pan H.F., Zhao X.F., Yuan H., et al. Decreased serum IL-22 levels in patients with systemic lupus erythematosus. Clin. Chim. Acta 2009, 401:179-180.
13. Doreau A., Belot A., Bastid J., et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat. Immunol. 2009, 10:778-785.
14. Linker-Israeli M., Bakke A.C., Kitridou R.C., et al. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J. Immunol. 1983, 130:2651-2655.
15. Becker H., Stengl G., Stein M., et al. Analysis of proteins that interact with the IL-2 regulatory region in patients with rheumatic diseases. Clin. Exp. Immunol. 1995, 99:325-330.
16. Kahaleh M.B. Soluble immubologic products in scleroderma sera. Clin. Immunol. Immunopathol. 1991, 58:139-144.
17. Fraser J.D., Straus D., Weiss A. Signal transduction events leading to T-cell lymphokine gene expression. Immunol. Today 1993, 14:357-362.
18. Muegge K., Durum S.K. From cell code to gene code: Cytokines and transcription factors. New Biol. 1989, 1:239-246.
19. Crispín J.C., Tsokos G.C. Transcriptional regulation of IL-2 in health and autoimmunity. Autoimmun. Rev. 2009, 8:190-195.
20. Safford M., Collins S., Luzt M.A., et al. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat. Immunol. 2005, 6:472-480.
21. Skerka C., Decker E.L., Zipfel P.F. A regulatory element in the human interleukin 2 gene promoter is a binding site for the zinc finger proteins Sp1 and EGR-1. J. Biol. Chem. 1995, 270:22500-22506.
22. Collins S., Wolfraim L.A., Drake C.G., et al. Cutting Edge: TCR-induced NAB2 enhances T cell function by coactivating IL-2 transcription. J. Immunol. 2006, 177:8301-8305.
23. Mathenia J., Reyes-Cortes E., Williams S., et al. Impact of Fli-1 transcription factor on autoantibody and lupus nephritis in NZM2410 mice. Clin. Exp. Immunol. 2010, 162:362-371.
24. Ono M., Yaguchi H., Ohkura N., et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 2007, 446:685-689.
25. Prokunina L., Castillejo-López C., Oberg F., et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet. 2002, 32:666-669.
26. Jain J., Loh C., Rao A. Transcriptional regulation of the IL-2 gene. Curr. Opin. Immunol. 1995, 7:333-342.
27. Solomou E.E., Juang Y.T., Gourley M.F., et al. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J. Immunol. 2001, 166:4216-4222.
28. Tenbrock K., Kyttaris V.C., Ahlmann M., et al. The cyclic AMP response element modulator regulates transcription of the TCR-ζChain. J. Immunol. 2005, 17:5975-5980.
29. Kyttaris V.C., Juang Y.T., Tenbrock K., et al. Cyclic adenosine 5'-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J. Immunol. 2004, 173:3557-3563.
30. Rauen T., Benedyk K., Juang Y.T., et al. A novel intronic cAMP response element modulator (CREM) promoter is regulated by activator protein-1 (AP-1) and accounts for altered activation-induced CREM expression in T cells from patients with systemic lupus erythematosus. J. Biol. Chem. 2011, 286:32366-32372.
31. Juang Y.T., Rauen T., Wang Y., et al. Transcriptional activation of the cAMP-responsive modulator promoter in human T cells is regulated by protein phosphatase 2A-mediated dephosphorylation of SP-1 and reflects disease activity in patients with systemic lupus erythematosus. J. Biol. Chem. 2011, 286:1795-1801.
32. Daniel P.B., Rohrbach L., Habener J.F. Novel cyclic adenosine 3',5'-monophosphate (cAMP) response element modulator theta isoforms expressed by two newly identified cAMP-responsive promoters active in the testis. Endocrinology 2000, 141:3923-3930.
33. Cesare D.De., Sassone-Corsi P. Transcriptional regulation by cyclic AMP-responsive factors. Prog. Nucleic Acid Res. Mol. Biol. 2000, 64:343-369.
34. Platzer C., Fritsch E., Elsner T., et al. Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells. Eur. J. Immunol. 1999, 29:3098-3104.
35. Macián F., López-Rodríguez C., Rao A. Partners in transcription: NFAT and AP-1. Oncogene 2001, 20:2476-2489.
36. Wiederrecht G., Lam E., Hung S., et al. The mechanism of action of FK-506 and cyclosporin A. Ann. N. Y. Acad. Sci. 1993, 696:9-19.
37. Lee K.A., Masson N. Transcriptional regulation by CREB and its relatives. Biochim. Biophys. Acta 1993, 1174:221-223.
38. Juang Y.T., Wang Y., Solomou E.E., et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J. Clin. Invest. 2005, 115:996-1005.
39. Kyttaris V.C., Wang Y., Juang Y.T., et al. CAMP response element modulator α expression in patients with systemic lupus erythematosus. Lupus 2006, 15:840-844.
40. Powell J.D., Lerner C.G., Ewoldt G.R., et al. The -180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. J. Immunol. 1999, 163:6631-6639.
41. Shaywitz A.J., Greenberg M.E. CREB: A stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 1999, 68:821-861.
42. Tenbrock K., Juang Y.T., Gourley M.F., et al. Antisense cyclic adenosine 5'-monophosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus. J. Immunol. 2002, 169:4147-4152.
43. Tenbrock K., Juang Y.T., Tolnay M., et al. The cyclic adenosine 5'-monophosphate response element modulator suppresses IL-2 production in stimulated T cells by a chromatin-dependent mechanism. J. Immunol. 2003, 170:2971-2976.
44. Hughes C.C., Pober J.S. Transcriptional regulation of the interleukin-2 gene in normal human peripheral blood T cells. Convergence of costimulatory signals and differences from transformed T cells. J. Biol. Chem. 1996, 271:5369-5377.
45. Vaeth M., Gogishvili T., Bopp T., et al. Regulatory T cells facilitate the nuclear accumulation of inducible cAMP early repressor (ICER) and suppress nuclear factor of activated T cell c1 (NFATc1). Proc. Natl. Acad. Sci. USA 2011, 108:2480-2485.
46. Li D.H., Winslow M.M., Cao T.M., et al. Modulation of peripheral B cell tolerance by CD72 in a murine model. Arthritis Rheum. 2008, 58:192-204.
47. Hummler E., Cole T.J., Blendy J.A., et al. Targeted mutation of the CREB gene: Compensation within the CREB/ATF family of transcription factors. Proc. Natl. Acad. Sci. USA 1994, 91:5647-5651.
48. Tada Y., Nagasawa K., Yamauchi Y., et al. A defect in the protein kinase C system in T cells from patients with systemic lupus erythematosus. Clin. Immunol. Immunopathol. 1991, 60:220-231.
49. Cedeño S., Cifarelli D.F., Blasini A.M., et al. Defective activity of ERK-1 and ERK-2 mitogen-activated protein kinases in peripheral blood T lymphocytes from patients with systemic lupus erythematosus: Potential role of altered coupling of Ras guanine nucleotide exchange factor hSos to adapter protein Grb2 in lupus T cells. Clin. Immunol. 2003, 106:41-49.
50. Kammer G.M. Deficient protein kinase A in systemic lupus erythematosus: A disorder of T lymphocyte signal transduction. Ann. N. Y. Acad. Sci. 2002, 968:96-105.
51. Foulkes N.S., Laoide B.M., Schlotter F., et al. Transcriptional antagonist cAMP-responsive element modulator (CREM) down-regulates c-fos cAMP-induced expression. Proc. Natl. Acad. Sci. USA 1991, 88:5448-5452.
52. Trabandt A., Aicher W.K., Gay R.E., et al. Spontaneous expression of immediately-early response genes c-fos and egr-1 in collagenase-producing rheumatoid synovial fibroblasts. Rheumatol. Int. 1992, 12:53-59.
53. Hikasa M., Yamamoto E., Kawasaki H., et al. P21waf1/cip1 is down-regulated in conjunction with up-regulation of c-Fos in the lymphocytes of rheumatoid arthritis patients. Biochem. Biophys. Res. Commun. 2003, 304:143-147.
54. Han Z., Boyle D.L., Manning A.M., et al. AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998, 28:197-208.
55. Liossis S.N., Ding X.Z., Dennis G.J., et al. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J. Clin. Invest. 1998, 101:1448-1457.
56. Asahara H., Santoso B., Guzman E., et al. Chromatin-dependent cooperativity between constitutive and inducible activation domains in CREB. Mol. Cell. Biol. 2001, 21:7892-7900.
57. Tenbrock K., Juang Y.T., Leukert N., et al. The transcriptional repressor cAMP response element modulator α interacts with histone deacetylase 1 to repress promoter activity. J. Immunol. 2006, 177:6159-6164.
58. Mishra N., Reilly C.M., Brown D.R., et al. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 2003, 111:539-552.
59. Zhao M., Sun Y., Gao F., et al. Epigenetics and SLE: RFX1 downregulation causes CD11a and CD70 overexpression by altering epigenetic modifications in lupus CD4+ T cells. J. Autoimmun. 2010, 35:58-69.
60. Lu Z.P., Ju Z.L., Sh G.Y., et al. Histone deacetylase inhibitor Trichostatin A reduces anti-DNA autoantibody production and represses IgH gene transcription. Biochem. Biophys. Res. Commun. 2005, 330:204-209.
61. Ahlmann M., Varga G., Sturm K., et al. The cyclic AMP response element modulator alpha suppresses CD86 expression and APC function. J. Immunol. 2009, 182:4167-4174.
62. Tsokos G.C., Kovacs B., Liossis S.N. Lymphocytes, cytokines, inflammation, and immune trafficking. Curr. Opin. Rheumatol. 1997, 9:380-386.
63. Krishnan S., Warke V.G., Nambiar M.P., et al. The FcR gamma subunit and SYK kinase replace the CD3 zeta-chain and ZAP-70 kinase in the TCR signaling complex of human effector CD4 T cells. J. Immunol. 2003, 170:4189-4195.
64. Krishnan S., Juang Y.T., Chowdhury B., et al. Differential expression and molecular associations of SYK in systemic lupus erythematosus T cells. J. Immunol. 2008, 181:8145-8152.
65. Deng G.M., Liu L., Bahjat F.R., et al. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum. 2010, 62:2086-2092.
66. Ghosh D., Kis-Toth K., Juang Y.T., et al. CREMα suppresses spleen tyrosine kinase expression in normal but not in SLE T cells. Arthritis Rheum. 2012, 64:799-807.
67. Foulkes N.S., Borrelli E., Sassone-Corsi P. CREM gene: Use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription. Cell 1991, 64:739-749.